Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
Clinical trial NCT05227118 · COMPLETED
Trial details
- NCT number
- NCT05227118
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2023-01-10
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.